As the most common types of cancer among women in the world with an estimated 2,088,849 new cases at 2018, breast cancer is responsible for 15.0% of deaths in females.
| INTRODUC TI ON
As the most common types of cancer among women in the world with an estimated 2,088,849 new cases at 2018, breast cancer is responsible for 15 .0% of deaths in females. 1 At present, breast cancer has been recognized as a heterogeneous disease which can be categorized into different pathological subtypes according to the status of estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). 2, 3 Triple negative breast cancer is the most aggressive subtype accounting for 10%-20% of all breast cancer cases, and characterized by lacking expression of ER, PR and HER2. 4, 5 Due to the lack of effective treatment including target therapy and endocrine therapy, it is useful to elucidate the mechanisms about triple negative breast cancer progression for developing novel therapies.
In our previous study, we identified olfactomedin 4 (OLFM4) as tumour-suppressing gene to suppress cell migration and invasion through controlling MMP9 in triple negative breast cancer. 6 Meanwhile, down-regulation of OLFM4 expression was correlated with present lymph node metastasis, distant metastasis, advanced clinical stage and poor prognosis in triple-negative breast cancer patients. 6 Furthermore, we found miR-103 functioned as oncogenic microRNA to modulate triple negative breast cancer cell migration and invasion through targeting OLFM4 expression. 7 Long non-coding RNAs are a subgroup of non-coding RNAs composed of more than 200 nucleotides. 8, 9 Recently, lncRNA MIR503 host gene (MIR503HG) has been suggested to be dysregulated and function as tumour-suppressing lncRNA in a variety of human cancers. 10 
| Cell lines
Two human triple negative breast cancer cell lines (MDA-MB-231
and TB549) and a human normal breast epithelial cell line (MCF-10A)
were cultured according to our previous description. 
| RT-PCR analysis
RNA isolation and MIR503HG expression determination was carried out according to previous description. 6 The primers are as follows:
MIR503HG, (forward) 5'-AAGGAATCCTCTCCCACCATTT-3' and (reverse) 5'-ACTCATTTGGCGGGAAAAC-3'. The miR-103 expression measure was performed as described in a previous report. 
| Western blot
Western blotting was performed with a SDS-PAGE Electrophoresis System according to previous report 6 with the following antibodies:
OLFM4 (Billerica, MA), MMP 9 (Cell Signalling Technology, Beverly, MA) and β-actin antibody (CWBIO, Jiangsu, China).
| Cell transfection
The full-length sequence MIR503HG cDNA was amplified by PCR, and cloned into pcDNA3.1 express vector to make a MIR503HG overexpression vector (pcDNA-MIR503HG 
| Cell migration and invasion assays
Cell migration and invasion experiments were conducted by transwell chambers with 8 mm pores (Corning, Cambridge, MA) according to previous description. 
| RE SULTS

| MIR503HG is down-regulated in triplenegative breast cancer tissues and cell lines
The relative expression of MIR503HG in primary triple-negative breast cancer tissue samples and corresponding adjacent normal mammary tissue samples was measured using qRT-PCR. Compared with adjacent normal mammary tissue samples, MIR503HG expression was markedly decreased in primary triple-negative breast cancer tissue samples (P < 0.001, Figure 1A ). Moreover, we also measured the relative ex- 
| MIR503HG is associated with malignant status of triple-negative breast cancer patients
For exploring the clinical significance of MIR503HG in triple-negative breast cancer patient, all cases were classified into the low MIR503HG expression group (n = 47) and the high MIR503HG expression group (n = 47) based on the median expression of MIR503HG. 7 Correlations between MIR503HG expression and clinicopathological features of triple-negative breast cancer patients were summarized in Table 1 . We observed low MIR503HG expression obviously correlated with clinical stage (I-II vs III-IV, P < 0.001), lymph node metastasis (N classification, N0-N1 vs N2-N3, P < 0.001) and distant metastasis (M classification, M0 vs M1, P = 0.001). However, MIR503HG expression had no association with age (P = 0.365), tumour size (T classification, P = 0.055), family history (P = 0.135) and histological grade (P = 0.835).
| MIR503HG is associated with poor prognosis in triple-negative breast cancer patients
For exploring the prognostic value of MIR503HG in triple-negative breast cancer patient, we estimated the relationship of MIR503HG expression and overall survival by Kaplan-Meier method. We found triple-negative breast cancer patients with low MIR503HG expression had a statistically significant worse prognosis compared with those with high MIR503HG expression (P < 0.001, Figure 2 ). Furthermore, we evaluated the prognostic factors for overall survival in triple-negative breast cancer patients, and found clinical stage (P = 0.004), T classification (P = 0.006), N classification (P = 0.016), M classification (P < 0.001) and MIR503HG expression (P < 0.001) were identified as prognostic factors through univariate Cox regression models (Table 2) . Then, low MIR503HG expression was further identified as a poor independent prognostic factor for triple-negative breast cancer patients through multivariate Cox regression models (P = 0.014, Table 2 ).
| MIR503HG directly interacts with miR-103 in triple-negative breast cancer
The bioinformatics analysis was conducted using online prediction tool (Starbase, http://starbase.sysu.edu.cn/) to search for lncRNAs paired with miR-103. The data suggested that there were putative binding sites between MIR503HG and miR-103
( Figure 3A) . Furthermore, luciferase reporter gene assay revealed that miR-103 directly targeted of MIR503HG-wt to negatively regulate the luciferase activity of MIR503HG-wt, rather than MIR503HG-mut (P < 0.001, Figure 3B ). The above findings suggested that miR-103 was a target of MIR503HG in triple-negative breast cancer cells. We observed that the expression of MIR503HG was negatively correlated with miR-103 expression in triple-negative breast cancer tissues (P < 0.001, Table 3 ). Furthermore, we investigated the effect of MIR503HG on miR-103 expression in triple-negative breast cancer cells, and found up-regulation of MIR503HG expression significantly elevated miR-103 expression (P = 0.001, Figure 4A ) and down-regulation of MIR503HG expression greatly reduced miR-103 expression (P = 0.007, Figure 4A ). Moreover, we investigated the impact of miR-103 on MIR503HG expression in triple-negative breast cancer cells, and suggested miR-103 mimics or miR-103 inhibitor had no significant effect on MIR503HG expression (P > 0.05, Figure 4B ).
| MIR503HG interacts with miR-103 to regulate cell migration and invasion in triple-negative breast cancer
To explore the effects of MIR503HG on triple-negative breast cancer cell migration and invasion, transwell cell migration and invasion assays were conducted. The results showed up-regulation of MIR503HG expression led to a decrease of cell migration and invasion ability in TB549 cell, and down-regulation of MIR503HG expression led to a increase of cell migration and invasion ability in MDA-MB-231 cell (P < 0.001, Figure 5A ,B). Moreover, rescue experiments were conducted to interpret whether MIR503HG regulated cell migration and invasion via miR-103 in triple-negative breast cancer. We found co-transfection of siRNA-MIR503HG and miR-103 inhibitor could rescue the facilitation of siRNA-MIR503HG in cell migration and invasion (P < 0.001, Figure 5A ,B), and co-transfection of pcDNA-MIR503HG and miR-103 inhibitor could not enhance the inhibition of pcDNA-MIR503HG in cell migration and invasion (P > 0.05, Figure 5A ,B).
| OLFM4 as the target gene of miR-103 is modulated by MIR503HG in triple-negative breast cancer
Our previous report suggested miR-103 functioned as oncogenic microRNA to modulate triple negative breast cancer cell migration and invasion through targeting OLFM4 expression. 7 Above results 
TA B L E 1
| D ISCUSS I ON
MIR503HG is the host gene of miR503, and located on chromosome Xq26.3, which is a region enriched for genes associated with human reproduction. 11 Originally, MIR503HG was identified to be involved in human endothelial cells and angiogenic processes. 12 Soon afterwards, Muys et al 13 found MIR503HG expression was increased in placenta, other reproductive tissues and 50% cancer cell lines.
Then, Zhang et al 14 found MIR503HG as an up-regulated lncRNA in colorectal cancer tissues through analysing RNA-seq datasets.
Moreover, Chung et al 15 performed oligonucleotide arrays for identifying aberrantly expressed lncRNAs, and found MIR503HG
was one of top-five non-coding genes, and showed high expression levels in anaplastic large-cell lymphoma. On the contrary, MIR503HG was suggested to be down-regulated in hepatocellular carcinoma 16 and oral squamous cell carcinoma. 17 However, the MIR503HG expression in breast cancer was still unknown. In conclusion, Low MIR503HG expression is observed in triple-negative breast cancer tissues and cells, and associated with malignant status and unfavourable overall survival in triple-negative breast cancer patients. MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer.
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